Compounds · Semaglutide · continued
The C-cell question: rodent findings and their human context — what changed since posts 61–66
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
1 like 22mo
g.haaland, post #50: Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable. A partial answer, offered because a partial answer beats none. Go to post
The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.
Written from notes rather than memory, which is why the numbers are specific.
Building on post #63 rather than restating it.
Reading back through the c-cell question threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
6 likes 22mo
This topic was referenced in
- Semaglutide and alcohol: what is actually documentedCompounds › Semaglutide · 18 replies
Promoted into the documentation commons. The content of this topic is maintained at Dulaglutide — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.
This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question…
|
+58 | 62 | 49k | 20mo |
|
Comparing the STEP programme populations: who was actually enrolled — the long version
On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. A narrow question about Comparing the STEP programme…
|
4 | 7.7k | 11mo | |
|
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I would like to know what people here actually do about semaglutide…
|
+14 | 18 | 10k | 2d |
|
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first…
|
2 | 39k | 6mo | |
|
Is there a ceiling dose beyond which semaglutide stops adding benefit?
Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because…
|
2 | 14k | 2mo |
Related topics — sharing the tags effect size, SELECT trial, randomised trial
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
The most common factual error about semaglutide on the internet
On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a compound…
|
2 | 49k | 2y | |
|
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. A question about GIP receptor agonism that I think has a definite answer, unlike…
|
2 | 867 | 10mo | |
|
Seven-day rolling means and why weekly readings mislead
Seven-day rolling means and why weekly readings mislead Writing it up because I had to work it out twice and would rather nobody else did. Posting a series rather than a conclusion, with the method first.…
|
+109 | 125 | 42k | 10h |
|
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version
Posting this under the heading it deserves: Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Everything below is what sits behind that. I have read the maintained page…
|
+138 | 148 | 1.8k | 2y |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
|
+150 | 163 | 22k | 11mo |